Jiménez, Isabel
Tazón-Vega, Bárbara
Abrisqueta, Pau
Nieto, Juan C.
Bobillo, Sabela
Palacio-García, Carles
Carabia, Júlia
Valdés-Mas, Rafael
Munuera, Magdalena
Puigdefàbregas, Lluís
Parra, Genís
Esteve-Codina, Anna
Franco-Jarava, Clara
Iacoboni, Gloria
Terol, María José
García-Marco, José Antonio
Crespo, Marta
Bosch, Francesc http://orcid.org/0000-0001-9241-2886
Funding for this research was provided by:
Instituto de Salud Carlos III (PI17/00950, PI18/01392, PI17/00943, PT17/0009/0019)
Fundación Científica Asociación Española Contra el Cáncer
Gilead Foundation (GLD16/00144, GLD18/00047)
Fundació la Marató de TV3 (201905-30-31)
Fundación Alfonso Martín Escudero
Ministerio de Ciencia, Innovación y Universidades (PTQ-16-08623, RYC-2012-2018)
Article History
Received: 2 December 2020
Accepted: 26 April 2021
First Online: 20 May 2021
Declarations
:
: A written informed consent was obtained from all individuals in accordance with the declaration of Helsinki and the study was approved by the clinical research ethics committee at Vall d’Hebron Hospital Universitari.
: Not applicable.
: P.A. has received honoraria from Janssen, Roche, Celgene and AbbVie. G.I. has received honoraria from Celgene, Novartis, Roche, AbbVie, Janssen and Gilead. J.A.G-M. has received research funding and honoraria from Roche, Janssen and AbbVie. M.C. has received research funding from, Pharmacyclics, Roche, ArQule and AstraZeneca. F.B. has received research funding and honoraria from Roche, Celgene, Takeda, AstraZeneca, Novartis, AbbVie and Janssen. All remaining authors have declared no conflicts of interest.